Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
JunD protects against chronic kidney disease by regulating paracrine mitogens
Evangéline Pillebout, … , Gérard Friedlander, Fabiola Terzi
Evangéline Pillebout, … , Gérard Friedlander, Fabiola Terzi
Published September 15, 2003
Citation Information: J Clin Invest. 2003;112(6):843-852. https://doi.org/10.1172/JCI17647.
View: Text | PDF
Article Nephrology Article has an altmetric score of 3

JunD protects against chronic kidney disease by regulating paracrine mitogens

  • Text
  • PDF
Abstract

The AP-1 transcription factor, composed of Jun and Fos proteins, plays a crucial role in the fine tuning of cell proliferation. We showed previously that AP-1 complexes are activated during the proliferative response that parallels the development of renal lesions after nephron reduction, but little is known about the specific role of individual Jun/Fos components in the deterioration process. Here we used JunD knockout (JunD–/–) mice and an experimental model of chronic renal injury (75% nephron reduction) to explore the role of JunD. Nephron reduction resulted in an initial compensatory growth phase that did not require JunD. JunD, however, was essential to inhibit a second wave of cell proliferation and to halt the development of severe glomerular sclerosis, tubular dilation, and interstitial fibrosis. We show that the effects of junD inactivation are not cell autonomous and involve upregulation of the paracrine mitogen, TGF-α. Expression of a transgene (REM) encoding a dominant negative isoform of the EGFR, the receptor for TGF-α, prevented the second wave of cell proliferation and the development of renal lesions in bitransgenic JunD–/–/REM mice. We propose that JunD is part of a regulatory network that controls proliferation to prevent pathological progression in chronic renal diseases.

Authors

Evangéline Pillebout, Jonathan B. Weitzman, Martine Burtin, Carla Martino, Pierre Federici, Moshe Yaniv, Gérard Friedlander, Fabiola Terzi

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Increased tubular cell proliferation in the absence of JunD. (a) The num...
Increased tubular cell proliferation in the absence of JunD. (a) The number of PCNA-positive cells per tubular section was measured in control kidneys (gray bar) and in JunD+/+ (white bars) and JunD–/– (black bars) remnant kidneys 7, 14, 30, and 60 days after nephron reduction. Data are mean ± SEM; n = 4–6 for each time point. ***P < 0.001, remnant versus control kidneys; ###P < 0.001, JunD–/– versus JunD+/+ by ANOVA, followed by Tukey-Kramer test. (b) PCNA and β-gal immunostaining in serial 4-μm sections of JunD–/– remnant kidneys at day 60 (×200). (c) Colocalization experiments in serial sections of JunD–/– remnant kidneys at day 60. Upper panels: overlay of β-gal staining and LTL staining (left) or Tamm-Horsfall staining (right). Lower panels: overlay of PCNA staining and LTL staining (left) or Tamm-Horsfall staining (right). (×200).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
9 readers on Mendeley
See more details